Another example in which RVAS has enhanced our understanding of a known hematopoietic regulator is exemplified by human variation impacting RUNX1. Germline mutations leading to RUNX1 deficiency cause familial platelet disorder with predisposition to myeloid leukemia (FPDMM). This evidence concerns the gene RUNX1 and blood platelet disease.